Imunoterapia específica em época de pandemia de COVID-19
Nelson Augusto Rosario Filho; José Luiz de Magalhães Rios; José Laerte Boechat Morandi; João Negreiros Tebyriçá; Geórgia Véras de Araújo Gueiros Lira; Martti A. Antila; Veridiana Aun Rufino Pereira; Filipe Wanick Sarinho; Norma de Paula Motta Rubini
Referências
1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-172.
2. Del Rio C, Malani PN. COVID-19-New Insights on a Rapidly Changing Epidemic [published online ahead of print, 2020 Feb 28]. JAMA. 2020;10.1001/jama.2020.3072. doi:10.1001/jama.2020.3072
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/ jama.2020.2648. Online ahead of print.
4. Golden DBK, Bernstein DI, Freeman TM, Tracy JM, Lang DM, Nicklas RA. AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report. J Allergy Clin Immunol Pract. 2017;5(2):330-2.
5. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28-54.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email